Date: August 18, 2017  Administrative Circular: 2017:12

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2: Immunization, Part 1 – Immunization Schedules, Part 2 – Immunization of Special Populations, Part 4 – Biological Products, Part 5 – Adverse Events Following Immunization & Supporting Documents

Part 1-Immunization Schedules

2. Routine Schedules

- **2.1 Schedule A & 2.2 Schedule B**
  These schedules have been updated to reflect the addition of boys to the Grade 6 HPV program.

- **2.3 Schedule C & 2.4 Schedule D**
  These schedules have been updated to reflect the addition of boys to the Grade 6 HPV program, as well as including clarification regarding the indication for a 2-dose series if the series was initiated prior to the 15th birthday.

Please remove page numbers: 5-7 & 9 dated May 2017
Please add new page numbers: 5-7 & 9 dated August 2017

Part 2-Immunization of Special Populations

**Specific Immunocompromising Conditions: Candidate For or Recipient Of Solid Organ or Islet Cell Transplant**

- **Table 1 & Table 2**
  These schedules have been updated to reflect the addition of boys to the Grade 6 HPV program.

- **Worksheet for Immunization of Adult Solid Organ Transplant Candidates and Recipients**
  Worksheet has been updated to include “HPV9 (eligible individuals only)”.

Please remove page numbers: 3-5 dated January 2017
Please add new page numbers: 3-5 dated August 2017
Part 4-Biological Products

Human Papillomavirus Vaccine (Nonavalent) (GARDASIL®9)

- INDICATIONS have been revised as follows:
  - “Females born on or after January 1, 2005 and who are in grade 6 or older” has been revised to “Individuals born on or after January 1, 2006 and who are in grade 6 or older”. The associated footnote indicating a complete series of GARDASIL®9 for those who have previously received CERVARIX® or GARDASIL® has been removed for this indication.
  - “Unimmunized or incompletely immunized females born in 1994-2004” has been revised to “Unimmunized or incompletely immunized females born in 1994-2005”.
  - HIV positive males and HIV positive females have been combined as a single indication.
  - “Transgender individuals 9-26 years of age (inclusive)” has been added.

Please remove page numbers: 1 & 2 dated May 2017
Please add new page numbers: 1 & 2 dated August 2017

2017/18 Seasonal Influenza Vaccines

- Influenza pages for the 2017/18 season have been revised. Eligibility criteria for publicly funded influenza vaccine remain the same as in the previous season.
- Revisions to the influenza pages include:
  - The vaccine strains contained in the 2017/18 influenza vaccines.
  - Removal of Fluad®. This product is not publicly funded in BC for the 2017/18 season. Fluviral® and Agriflu® are the intended products for adults 18 years of age and older.
  - Intended Use of Influenza Vaccines: the table has been revised to combine the age groups of “18-64 years” & “65 years and older” into the one age group “18 years of age and older”. Content has also been added regarding the purchase of non-publicly funded vaccines, as well as a link to the Health Care Provider Question & Answer Document related to FLUZONE® High-Dose vaccine.
- Safety Issues Applicable to Influenza Vaccines: this page has been reviewed and no content changes have been made.

Please remove the following pages:
- 2016/17 Seasonal Influenza Vaccines: page 1 dated August 2016
- Intended Use of Influenza Vaccines: page 1 dated August 2016
- FLUMIST® QUADRIVALENT: pages 1-3 dated August 2016
- FLULAVAL® TETRA: pages 1 & 2 dated August 2016
- FLUVIRAL®: pages 1 & 2 dated August 2016
- AGRIFLU®: pages 1 & 2 dated August 2016
- FLUAD®: pages 1 & 2 dated August 2016
Part 5 – Adverse Events Following Immunization

- Content related to the reporting of an adverse event following the administration of a non-vaccine product has been updated for clarity:
  - The Adverse Event Following Immunization (AEFI) reporting system including Panorama reporting module is designed for active immunizing products (i.e., vaccines) and completion of the AEFI Case Report Form will result in a report through Panorama or PARIS (Vancouver Coastal Health) to the Public Health Agency of Canada. Adverse events following receipt of a passive immunizing agent (e.g., immune globulin) or diagnostic agent (e.g., tuberculin skin test), should be reported using the procedures for reporting an adverse drug reaction to the Canadian Adverse Drug Reaction Monitoring Program at Health Canada.

  - An AEFI report should be completed for an adverse event that follows administration of an active immunizing agent (i.e., vaccine) that is administered at the same visit with a passive immunizing agent (e.g., immune globulin) or a diagnostic agent (e.g., tuberculin skin test), if the event is thought to be associated with the vaccine, or if the associated product is uncertain. If the adverse event is thought to be related to the passive immunizing agent or diagnostic agent, the event should also be reported to the Canadian Adverse Drug Reaction Monitoring Program at Health Canada, in addition to reporting as an AEFI. Further details on how to report such occurrences in Panorama are contained in the AEFI Panorama reporting guidelines, located on the Surveillance Forms page of the BCCDC website, within the AEFI section.
Supporting Documents

History of Immunization in BC

- School Immunization Programs updated to include the addition of boys to the Grade 6 HPV program.
- Human Papillomavirus Vaccine updated to include the addition of Grade 6 boys and transgender individuals 9-26 years of age.

Please remove page numbers: 1 & 9 dated May 2017
Please add new page numbers: 1 & 9 dated August 2017

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: christine.halpert@bccdc.ca) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
   Dr. Perry Kendall
   Provincial Health Officer

   Dr. Bonnie Henry
   Deputy Provincial Health Officer

   Craig Thompson
   Director, Provincial Immunization Services

   Warren O’Briain
   Executive Director, Public Health Services & Office of Aboriginal Health